Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Dalpiciclib + Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
NCT06149130Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2024
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in breast cancer, sponsored by Tongji Hospital. Started Jan 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06149130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149130.